Dashboard
Manage Tickers

GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 83.17 $ 0.14 (0.17 %)    

Monday, 16-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.01 $ -0.05 (-0.01 %)
DIA $ 417.33 $ 0.38 (0.09 %)
SPY $ 562.87 $ 1.40 (0.25 %)
TLT $ 101.29 $ 0.66 (0.65 %)
GLD $ 238.61 $ 0.01 (0 %)
$ 82.81
$ 83.03
$ 83.15 x 100
-- x --
$ 82.54 - $ 83.58
$ 60.75 - $ 85.12
6,530,266
na
103.1B
$ 0.30
$ 97.82
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-24-2016 12-31-2015 10-K
36 11-04-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-25-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
09/16/2024 15:47:13

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

100-invested-in-this-stock-20-years-ago-would-be-worth-900-today
$100 Invested In This Stock 20 Years Ago W...
09/13/2024 16:00:58

marengo-therapeutics-enters-clinical-study-collaboration-and-supply-agreement-with-gilead-sciences
Marengo Therapeutics Enters Clinical Study...
09/13/2024 11:06:14

The collaboration plans to evaluate the combination of Marengo's first-in-class TCR Vβ selective dual T cell agonist, STAR0...

gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventing-hiv-infections
Gilead Unveils 'Remarkable Outcomes' From ...
09/12/2024 17:46:36

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...

what-the-options-market-tells-us-about-gilead-sciences
What the Options Market Tells Us About Gil...
09/12/2024 15:02:49

gilead-announces-results-of-interim-analysis-from-second-phase-3-trial-showing-twice-yearly-lenacapavir-reduced-hiv-infections-by-96
Gilead Announces Results Of Interim Analys...
09/12/2024 12:36:05

piper-sandler-maintains-overweight-on-gilead-sciences-maintains-95-price-target
Piper Sandler Maintains Overweight on Gile...
09/11/2024 13:55:21

Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $95 price tar...

gilead-sciences-and-genesis-therapeutics-announce-strategic-collaboration-to-develop-novel-small-molecule-therapies-gilead-gains-exclusive-rights-to-develop-and-commercialize-products-using-genesiss-gems-ai-platform-for-target-optimization
Gilead Sciences And Genesis Therapeutics A...
09/10/2024 12:04:31

Core News & Articles
AstraZeneca Says Datopotamab Deruxtecan Sh...
09/09/2024 17:55:38

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
09/09/2024 15:38:20

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
09/06/2024 19:00:21

gilead-to-present-new-trodelvy-data-at-the-iaslc-2024-world-conference-on-lung-cancer
Gilead To Present New Trodelvy Data At The...
09/05/2024 12:12:48

-Data Span Multiple Types of Lung Cancer and Lines of Therapy-Gilead Sciences, Inc. (NASDAQ:GILD) will present new data from th...

unveiling-10-analyst-insights-on-gilead-sciences
Unveiling 10 Analyst Insights On Gilead Sc...
09/04/2024 14:00:45

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-74
RBC Capital Maintains Sector Perform on Gi...
09/04/2024 13:15:08

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

mercks-death-cross-vs-gileads-golden-cross-pharma-giants-diverge-on-wall-street
Merck's Death Cross Vs. Gilead's Golden Cr...
09/03/2024 20:17:53

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging techn...

gilead-sciences-options-trading-a-deep-dive-into-market-sentiment
Gilead Sciences Options Trading: A Deep Di...
09/03/2024 16:30:32

avenzo-therapeutics-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-avzo-021-and-trodelvy-in-hrher2--metastatic-breast-cancer
Avenzo Therapeutics Announces Clinical Stu...
09/03/2024 13:03:49

AVZO-021, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Trodelvy (sacituzumab govitecan-hziy), ...

decoding-gilead-sciencess-options-activity-whats-the-big-picture
Decoding Gilead Sciences's Options Activit...
08/27/2024 18:00:52

100-invested-in-this-stock-20-years-ago-would-be-worth-900-today
$100 Invested In This Stock 20 Years Ago W...
08/22/2024 16:01:05

peering-into-gilead-sciencess-recent-short-interest
Peering Into Gilead Sciences's Recent Shor...
08/20/2024 16:00:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION